However, in a pre-established B16 tumors model, TAMs were the major source of IFN-β upon treatment of STING agonists (ML-RR-S2 CDA and DMXAA) compared to DCs, T cells, and tumor cells 44. This evidence concerns the gene IFNB1 and neoplasm.